{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:33Z","timestamp":1794047493396,"version":"4.8.0"},"reference-count":54,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"8","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Continuous treatment with ibrutinib not only exerts tumor control but also enhances T-cell function in patients with chronic lymphocytic leukemia (CLL). We conducted longitudinal multi-omics analyses in samples from CLL patients receiving ibrutinib upfront to identify potential adaptive mechanisms to Bruton tyrosine kinase (BTK) inhibition during the first 12 months of continuous therapy. We found that ibrutinib induced a decrease in the expression of exhaustion markers and the proportion of regulatory T cells and T-follicular helper cells normalized to levels observed in healthy donors. Functionally, the expression of genes related to activation, proliferation, differentiation, and metabolism were downregulated in T cells; after in vitro stimulation, proliferation capacity was only slightly modified by ibrutinib treatment, while cytokine production was increased. In CLL cells, we observed a downregulation of immunosuppression, adhesion, and migration proteins. Adaptation at molecular level, characterized by an increase in cancer cell fraction of CLL cells with mutated driver genes, was observed in around half of the patients and was associated with retained migrative capacity towards CXCL12\/CXCR4 axis. Interestingly, BTK C481S mutations were detected as early as after 6 months of treatment, particularly enriched in subsets of malignant cells retaining migrative capacity. These CLL cells with potential migrative capacity under ibrutinib also exhibited a distinct transcriptomic profile including upregulation of mTOR-AKT and MYC pathways. We identified the high expression of TMBIM6 as a potential novel independent poor prognostic factor. Of note, BIA, a TMBIM6 antagonist, induced CLL cell apoptosis and synergized with ibrutinib. In summary, our comprehensive multi-omics analysis of CLL patients undergoing ibrutinib therapy has unveiled early immunomodulatory effects on T cells and adaptative mechanisms in CLL cells. These findings can contribute to the identification of resistance mechanisms and the discovery of novel therapeutic targets.<\/jats:p>","DOI":"10.3324\/haematol.2024.286663","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T04:41:47Z","timestamp":1741840907000},"page":"1758-1773","source":"Crossref","is-referenced-by-count":3,"title":["Bruton tyrosine kinase covalent inhibition shapes the immune microenvironment in chronic lymphocytic leukemia"],"prefix":"10.3324","volume":"110","author":[{"given":"Daniel","family":"Medina-Gil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Palomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"L\u00e1zaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Mart\u00edn-Mur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Castells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau Marc","family":"Mu\u00f1oz-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlota","family":"Pag\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Pujadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Esteve-Codina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Cabirta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Ferr\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Alcoceba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jos\u00e9","family":"Terol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Andreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merc\u00e8","family":"Mart\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Abrisqueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spanish Group of","family":"Chronic Lymphocytic Leukemia - GELLC","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"77329","doi-asserted-by":"crossref","unstructured":"O\u2019Brien S, Furman RR, Coutre S. Single-agent ibrutinib in treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018; 131(17):1910-1919.","DOI":"10.1182\/blood-2017-10-810044"},{"key":"77330","doi-asserted-by":"crossref","unstructured":"Burger JA, Barr PM, Robak T. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/ SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020; 34(3):787-798.","DOI":"10.1038\/s41375-019-0602-x"},{"key":"77331","doi-asserted-by":"crossref","unstructured":"Herman SEM, Gordon AL, Hertlein E. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011; 117(23):6287-6296.","DOI":"10.1182\/blood-2011-01-328484"},{"key":"77332","doi-asserted-by":"crossref","unstructured":"Ponader S, Chen S-S, Buggy JJ. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012; 119(5):1182-1189.","DOI":"10.1182\/blood-2011-10-386417"},{"key":"77333","doi-asserted-by":"crossref","unstructured":"de Rooij MFM, Kuil A, Geest CR. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor\u2013and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 2012; 119(11):2590-2594.","DOI":"10.1182\/blood-2011-11-390989"},{"key":"77334","doi-asserted-by":"crossref","unstructured":"Advani RH, Buggy JJ, Sharman JP. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. J Clin Oncol. 2013; 31(1):88-94.","DOI":"10.1200\/JCO.2012.42.7906"},{"key":"77335","doi-asserted-by":"crossref","unstructured":"Ramsay AG, Johnson AJ, Lee AM. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008; 118(7):2427-2437.","DOI":"10.1172\/JCI35017"},{"key":"77336","doi-asserted-by":"crossref","unstructured":"Riches JC, Davies JK, McClanahan F. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2013; 121(9):1612-1621.","DOI":"10.1182\/blood-2012-09-457531"},{"key":"77337","doi-asserted-by":"crossref","unstructured":"Jim\u00e9nez I, Taz\u00f3n-Vega B, Abrisqueta P. Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia. Biomark Res. 2021; 9(1):37.","DOI":"10.1186\/s40364-021-00290-z"},{"key":"77338","doi-asserted-by":"crossref","unstructured":"Dubovsky JA, Beckwith KA, Natarajan G. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013; 122(15):2539-2549.","DOI":"10.1182\/blood-2013-06-507947"},{"key":"77339","doi-asserted-by":"crossref","unstructured":"Niemann CU, Herman SEM, Maric I. Disruption of in vivo chronic lymphocytic leukemia tumor\u2013microenvironment interactions by ibrutinib\u2013findings from an investigator-initiated phase II study. Clin Cancer Res. 2016; 22(7):1572-1582.","DOI":"10.1158\/1078-0432.CCR-15-1965"},{"key":"77340","doi-asserted-by":"crossref","unstructured":"Long M, Beckwith K, Do P. Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest. 2017; 127(8):3052-3064.","DOI":"10.1172\/JCI89756"},{"key":"77341","doi-asserted-by":"crossref","unstructured":"Wiestner A. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia. Haematologica. 2015; 100(12):1495-1507.","DOI":"10.3324\/haematol.2014.119123"},{"key":"77342","doi-asserted-by":"crossref","unstructured":"Herman SEM, Montraveta A, Niemann CU. The Bruton tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia. Clin Cancer Res. 2017; 23(11):2831-2841.","DOI":"10.1158\/1078-0432.CCR-16-0463"},{"key":"77343","doi-asserted-by":"crossref","unstructured":"Puzzolo MC, Del Giudice I, Peragine N. TH2\/TH1 shift under ibrutinib treatment in chronic lymphocytic leukemia. Front Oncol. 2021; 11:637186.","DOI":"10.3389\/fonc.2021.637186"},{"key":"77344","doi-asserted-by":"crossref","unstructured":"Woyach JA, Furman RR, Liu T-M. Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014; 370(24):2286-2294.","DOI":"10.1056\/NEJMoa1400029"},{"key":"77345","doi-asserted-by":"crossref","unstructured":"Abrisqueta P, Gonz\u00e1lez-Barca E, Ferr\u00e0 C. Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC). EClinicalMedicine. 2024; 73:102642.","DOI":"10.1016\/j.eclinm.2024.102642"},{"key":"77346","doi-asserted-by":"crossref","unstructured":"Picelli S, Faridani OR, Bj\u00f6rklund \u00c5K, Winberg G, Sagasser S, Sandberg R. Full-length RNA-seq from single cells using Smart-seq2. Nat Protoc. 2014; 9(1):171-181.","DOI":"10.1038\/nprot.2014.006"},{"key":"77347","doi-asserted-by":"crossref","unstructured":"Purroy N, Abrisqueta P, Carabia J. Co-culture of primary CLL cells with bone marrow mesenchymal cells, CD40 ligand and CpG ODN promotes proliferation of chemoresistant CLL cells phenotypically comparable to those proliferating in vivo. Oncotarget. 2015; 6(10):7632-7643.","DOI":"10.18632\/oncotarget.2939"},{"key":"77348","doi-asserted-by":"crossref","unstructured":"Zheng S, Wang W, Aldahdooh J. SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets. Genomics Proteomics Bioinformatics. 2022; 20(3):587-596.","DOI":"10.1016\/j.gpb.2022.01.004"},{"key":"77349","doi-asserted-by":"crossref","unstructured":"Jain P, Javdan M, Feger FK. Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance. Haematologica. 2012; 97(4):599-607.","DOI":"10.3324\/haematol.2011.047316"},{"key":"77350","doi-asserted-by":"crossref","unstructured":"Cha Z, Zang Y, Guo H. Association of peripheral CD4+ CXCR5+ T cells with chronic lymphocytic leukemia. Tumor Biol. 2013; 34(6):3579-3585.","DOI":"10.1007\/s13277-013-0937-2"},{"key":"77351","doi-asserted-by":"crossref","unstructured":"Palma M, Gentilcore G, Heimersson K. T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers. Haematologica. 2017; 102(3):562-572.","DOI":"10.3324\/haematol.2016.151100"},{"key":"77352","doi-asserted-by":"crossref","unstructured":"Catakovic K, Gassner FJ, Ratswohl C. TIGIT expressing CD4+ T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia. Oncoimmunology. 2017; 7(1):e1371399.","DOI":"10.1080\/2162402X.2017.1371399"},{"key":"77353","doi-asserted-by":"crossref","unstructured":"DArena G, Laurenti L, Minervini MM. Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. Leuk Res. 2011; 35(3):363-368.","DOI":"10.1016\/j.leukres.2010.08.010"},{"key":"77354","doi-asserted-by":"crossref","unstructured":"Pascutti MF, Jak M, Tromp JM. IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells. Blood. 2013; 122(17):3010-3019.","DOI":"10.1182\/blood-2012-11-467670"},{"key":"77355","doi-asserted-by":"crossref","unstructured":"Supek F, Bo\u0161njak M, \u0160kunca N, \u0160muc T. REVIGO summarizes and visualizes long lists of gene ontology terms. PLoS One. 2011; 6(7):e21800.","DOI":"10.1371\/journal.pone.0021800"},{"key":"77356","doi-asserted-by":"crossref","unstructured":"Steen CB, Liu CL, Alizadeh AA, Newman AM. Profiling cell type abundance and expression in bulk tissues with CIBERSORTx. Methods Mol Biol. 2020; 2117:135-157.","DOI":"10.1007\/978-1-0716-0301-7_7"},{"key":"77357","doi-asserted-by":"crossref","unstructured":"Yan X-J, Dozmorov I, Li W. Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia. Blood. 2011; 118(19):5201-5210.","DOI":"10.1182\/blood-2011-03-342436"},{"key":"77358","doi-asserted-by":"crossref","unstructured":"Kondo K, Shaim H, Thompson PA. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1\/PD-L1 pathway. Leukemia. 2018; 32(4):960-970.","DOI":"10.1038\/leu.2017.304"},{"key":"77359","doi-asserted-by":"crossref","unstructured":"Herman SEM, Mustafa RZ, Jones J, Wong DH, Farooqui M, Wiestner A. Treatment with Ibrutinib inhibits BTK-and VLA-4-dependent adhesion of chronic lymphocytic leukemia cells in vivo. Clin Cancer Res. 2015; 21(20):4642-4651.","DOI":"10.1158\/1078-0432.CCR-15-0781"},{"key":"77360","doi-asserted-by":"crossref","unstructured":"Chen S-S, Chang BY, Chang S. BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. Leukemia. 2016; 30(4):833-843.","DOI":"10.1038\/leu.2015.316"},{"key":"77361","doi-asserted-by":"crossref","unstructured":"Calissano C, Damle RN, Marsilio S. Intraclonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born\/divided and older\/quiescent cells. Mol Med. 2011; 17:1374-1382.","DOI":"10.2119\/molmed.2011.00360"},{"key":"77362","doi-asserted-by":"crossref","unstructured":"Rey-Barroso J, Munaretto A, Rouqui\u00e9 N. Lymphocyte migration and retention properties affected by ibrutinib in chronic lymphocytic leukemia. Haematologica. 2024; 109(3):809-823.","DOI":"10.3324\/haematol.2022.282466"},{"key":"77363","doi-asserted-by":"crossref","unstructured":"Cosimo E, Tarafdar A, Moles MW. AKT\/mTORC2 inhibition activates FOXO1 function in CLL cells reducing B-cell receptor-mediated survival. Clin Cancer Res. 2019; 25(5):1574-1587.","DOI":"10.1158\/1078-0432.CCR-18-2036"},{"key":"77364","doi-asserted-by":"crossref","unstructured":"Lu J, Cannizzaro E, Meier-Abt F. Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPHOS activity in chronic lymphocytic leukemia. Nat Cancer. 2021; 2(8):853-864.","DOI":"10.1038\/s43018-021-00216-6"},{"key":"77365","doi-asserted-by":"crossref","unstructured":"Kohlhaas V, Blakemore SJ, Al-Maarri M. Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1. Blood. 2021; 137(5):646-660.","DOI":"10.1182\/blood.2020005734"},{"key":"77366","doi-asserted-by":"crossref","unstructured":"Seda V, Vojackova E, Ondrisova L. FoxO1-GAB1 axis regulates homing capacity and tonic AKT activity in chronic lymphocytic leukemia. Blood. 2021; 138(9):758-772.","DOI":"10.1182\/blood.2020008101"},{"key":"77367","doi-asserted-by":"crossref","unstructured":"Knisbacher BA, Lin Z, Hahn CK. Molecular map of chronic lymphocytic leukemia and its impact on outcome. Nat Genet. 2022; 54(11):1664-1674.","DOI":"10.1038\/s41588-022-01140-w"},{"key":"77368","doi-asserted-by":"crossref","unstructured":"Zhang M, Li X, Zhang Y, Zhou K. Bax inhibitor-1 mediates apoptosis-resistance in human nasopharyngeal carcinoma cells. Mol Cell Biochem. 2010; 333:1-7.","DOI":"10.1007\/s11010-009-0198-y"},{"key":"77369","doi-asserted-by":"crossref","unstructured":"Kim H-K, Bhattarai KR, Junjappa RP. TMBIM6\/BI-1 contributes to cancer progression through assembly with mTORC2 and AKT activation. Nat Commun. 2020; 11(1):4012.","DOI":"10.1038\/s41467-020-17802-4"},{"key":"77370","doi-asserted-by":"crossref","unstructured":"Solman IG, Blum LK, Hoh HY. Ibrutinib restores immune cell numbers and function in first-line and relapsed\/refractory chronic lymphocytic leukemia. Leuk Res. 2020; 97:106432.","DOI":"10.1016\/j.leukres.2020.106432"},{"key":"77371","doi-asserted-by":"crossref","unstructured":"Rendeiro AF, Krausgruber T, Fortelny N. Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL. Nat Commun. 2020; 11(1):577.","DOI":"10.1038\/s41467-019-14081-6"},{"key":"77372","doi-asserted-by":"crossref","unstructured":"Fraietta JA, Beckwith KA, Patel PR. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016; 127(9):1117-1127.","DOI":"10.1182\/blood-2015-11-679134"},{"key":"77373","doi-asserted-by":"crossref","unstructured":"Langerbeins P, Robrecht S, Nieper P. Ibrutinib in early-stage chronic lymphocytic leukemia: the randomized, placebocontrolled, double-blind, phase III CLL12 trial. J Clin Oncol. 2025; 43(4):392-402.","DOI":"10.1200\/JCO.24.00975"},{"key":"77374","doi-asserted-by":"crossref","unstructured":"Jim\u00e9nez M, Fern\u00e1ndez\u2010Naval C, Navarro V. Kinetics of cellular and humoral immunogenicity and effectiveness of SARS\u2010CoV\u20102 booster vaccination in hematologic neoplasms. Am J Hematol. 2023; 98(8):1204-1213.","DOI":"10.1002\/ajh.26951"},{"key":"77375","doi-asserted-by":"crossref","unstructured":"Xiao X, Lao X-M, Chen M-M. PD-1hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression. Cancer Discov. 2016; 6(5):546-559.","DOI":"10.1158\/2159-8290.CD-15-1408"},{"key":"77376","doi-asserted-by":"crossref","unstructured":"Chen S, Chiorazzi N. Functional consequences of inhibition of Bruton\u2019s tyrosine kinase by ibrutinib in chronic lymphocytic leukemia. Hematol Oncol. 2023; 41:119-128.","DOI":"10.1002\/hon.3144"},{"key":"77377","doi-asserted-by":"crossref","unstructured":"Mhibik M, Gaglione EM, Eik D. Cytotoxicity of the CD3\u00d7 CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting. Blood Adv. 2023; 7(15):4089-4101.","DOI":"10.1182\/bloodadvances.2022009517"},{"key":"77378","doi-asserted-by":"crossref","unstructured":"Ailawadhi S, Parrondo RD, Paulus A. Time-limited maintenance with ibrutinib after first-fine therapy and the incremental impact on minimal residual disease (MRD) for patients with chronic lymphocytic leukemia (CLL). Blood. 2022; 140(Suppl 1):9904-9905.","DOI":"10.1182\/blood-2022-164667"},{"key":"77379","doi-asserted-by":"crossref","unstructured":"Itsara A, Sun C, Bryer E. Long-term outcomes in chronic lymphocytic leukemia treated with ibrutinib: 10-year follow-up of a phase 2 study. Blood. 2023; 142(Suppl 1):201.","DOI":"10.1182\/blood-2023-182397"},{"key":"77380","doi-asserted-by":"crossref","unstructured":"Jain N, Keating M, Thompson P. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019; 380(22):2095-2103.","DOI":"10.1056\/NEJMoa1900574"},{"key":"77381","doi-asserted-by":"crossref","unstructured":"Sun C, Chen Y-C, Martinez Zurita A. The immune microenvironment shapes transcriptional and genetic heterogeneity in chronic lymphocytic leukemia. Blood Adv. 2023; 7(1):145-158.","DOI":"10.1182\/bloodadvances.2021006941"},{"key":"77382","doi-asserted-by":"crossref","unstructured":"Hsu C-F, Sui C-L, Wu W-C. Klf10 induces cell apoptosis through modulation of BI-1 expression and Ca2+ homeostasis in estrogen-responding adenocarcinoma cells. Int J Biochem Cell Biol. 2011; 43(4):666-673.","DOI":"10.1016\/j.biocel.2011.01.010"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/11975\/78181","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11975\/78622","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11975\/78181","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:08:21Z","timestamp":1794046101000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/11975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":54,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.286663","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,13]]}}}